Rubicon Research IPO
Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. Based on the peer set (of six listed Indian companies assessed by F&S, and the Company), it is the only Indian pharmaceutical player with a complete focus on regulated markets.
Rubicon Research IPO Details
| Opening Date To be announced | Closing Date To be announced |
| Price Band To be announced | Issue Size To be announced |
| Face Value To be announced | Market Lot To be announced |
| Listing at NSE,BSE | |
Rubicon Research IPO Timeline (Tentative Schedule)
| IPO Open Date | To be announced |
|---|---|
| IPO Close Date | To be announced |
| Allotment Date | To be announced |
| Initiation Of Refunds | To be announced |
| Credit Of Shares To Demat Account | To be announced |
| IPO Listing Date | To be announced |
| UPI Mandate Expiry Date | To be announced |
Checkout the List of Upcoming IPO
Financial Highlights
| Period | Net Profit (In Cr.) | Revenue from operations (In Cr.) | Cash Flow from Operations (In Cr.) | Free Cash Flow ( in Cr.) | Margins |
|---|---|---|---|---|---|
| FY’24 | 91.01 | 853.89 | 21.01 | -35.04 | 19.8% |
| FY’23 | -16.89 | 393.52 | -74.75 | -119.15 | 10.5% |
| FY’22 | -67.12 | 313.57 | -62.63 | -117.14 | -6.8% |
Strengths & Weakness
| Strengths | Weaknesses | ||
|---|---|---|---|
| Fastest growing Indian pharmaceutical company amongst its peers and the only Indian company focused completely on the US market. | Manufacturing complexities and regulatory issues may impact sales, delay product launches, harm operations, or even lead to facility closures. | ||
| Data-driven framework enables it to build a diverse product portfolio, balancing new and specialty products to withstand pricing pressures. | Disruptions to R&D or manufacturing facilities can significantly impact business, operations, and cash flow. | ||
| Robust sales and distribution capabilities in the US. | Company’s success relies on executing growth strategies; failure to sustain or manage growth may harm business and financial health. | ||
| Strong track record of compliance combined with expertise in cost effective manufacturing. | Intense competition in the pharmaceutical industry could harm business and future growth prospects. | ||
How to apply in IPO via UPI on Dynami
A simple and smartest way to Apply in IPO online via Religare Dynami Mobile App
How to apply for Rubicon Research IPO?
Retail investors need to apply for the IPO using UPI
UPI
- Link your bank account to a UPI ID.
- Register your UPI id with your Demat account.
- Subscribe for Rubicon Research IPO and approve the payment on your UPI ID.
Demat Account
- If you are an existing Dynami user, Pre-Apply Now!
- If you’re a new investor, open free demat account with our Dynami App and begin your investment journey.
How to open a
Demat & Trading Account?
Fill up your personal details in the form above
Fill up your DOB, PAN, email & bank account details
Upload your photo and e-sign your application via Aadhaar OTP
Frequently Asked Questions
What is the price band of the IPO?
To be announced
What is the size of the company?
To be announced
What is the minimum lot size of the IPO?
To be announced
What is the minimum investment required?
To be announced
To remain updated on the latest
market updates follow us at
Copyright 2010 Religare. Trademarks are the property of their respective owners. All rights reserved. Please note that by submitting your mobile and email on our website, you are authorizing us to Call/SMS/Whtsapp/Email you even though you may be registered under DNC. We shall Call/SMS you for a period of 6 months
Religare Broking Limited (RBL): Registered Office: 2nd Floor, P-14, 45/90, P-Block, Connaught Place, New Delhi 110001. Board line number: 011-49871213. Fax No.: 011-49871189
Religare Broking Limited (CIN: U65999DL2016PLC314319) Registered Office: Religare Broking Limited, 2nd Floor, P-14, 45/90, P-Block, Connaught Place, New Delhi 110001. Board line number: 011-46272400, Fax No. 011-46272447. Member Religare Broking Limited (RBL) : SEBI Regn. No. INZ000174330 NSE CM, F&O, CD TM Code: 06537 Clearing Member (F&O) No. M50235; BSE CM, F&O, CD, CO Code: 3004 Clearing No: 3004; MSE CM, F&O, CD, TM Code: 1051| MCX Membership No. 56560 | NCDEX Membership No. 01276 | AMFI ARN No.139809. Depository Participant : Religare Broking Limited (RBL) – NSDL: DP ID: IN 301774 | SEBI Regn. No: IN-DP-385-2018 | CDSL DP ID: 30200 | SEBI Regn. No: IN-DP-385-2018. Research Analyst: Religare Broking Limited (RBL) – SEBI Regn. No: INH100006977 | Registrars to an issue and share Transfer Agents (RTA) - SEBI Regi. No : INR000004361 | Corporate Agent (Composite) - IRDA Regi. No : CA0581 | National Pension System - Point of Presence (NPS-POP) - PFRDA Regi. No : POP01092018.
Disclaimer : Investment in securities market are subject to market risks, read all the related documents carefully before investing. RBL is a distributor of Mutual Funds / IPOs / Insurance / Bonds & NCDs. Equities, Currencies & Depository Services are offered through Religare Broking Ltd. Brokerage will not exceed the SEBI prescribed limit. | Securities quoted are exemplary and are not recommendatory. |
https://religareonline.com/disclaimer